The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading

Journal of Medical Genetics

Volumn 41, Issue 1, 2004, Pages 6-10

  Livesey, K J ^b,g   Wimhurst, V L C ^b   Carter, K ^c   Worwood, M ^c   Cadet, E ^d   Rochette, J ^d   Roberts, A G ^c   Pointon, J J ^b   Merryweather Clarke, A T ^b   Bassett, M L ^e   Jouanolle, A M ^f   Mosser, A ^f   David, V ^f   Poulton, J ^a   Robson, K J H ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e CANBERRA HOSPITAL   (Australia)

^f UNIVERSITÉ DE RENNES 1   (France)

^g CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ADULT; ALLELE; ARTHROPATHY; ARTICLE; BLOOD ANALYSIS; BODY FAT; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES INSIPIDUS; FATIGUE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LIVER DISEASE; MAJOR CLINICAL STUDY; MITOCHONDRIAL DNA DISORDER; MULTIFACTORIAL GENETIC DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 9144251568     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2003.008805     Document Type: Article

References (62)

1. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, et al. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-98.
2. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
3. 2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
4. 2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997;94:12384-9.
5. Parkkila S, Waheed A, Britton RS, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997;94:13198-202.
6. Feder JN, Penny DN, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-7.
7. Waheed A, Parkkila S, Saarnio J, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci U S A 1999;96:1579-84.
8. Lebrón JA, West Jr AP, Bjorkman PJ. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999;294(1):239-45.
9. Bennett MJ, Lébron JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature 2000;403:46-53.
10. Bothwell TH, Charlton RW, Motulsky AG. Hemochromatosis. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995:2237-69.
11. Worwood M, Shearman JD, Wallace DF, et al. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997;41:841-4.
12. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-51.
13. Borot N, Roth M-P, Malfroy L, et al. Mutations in the MHC class I-like gene for hemochromatosis in French patients. Immunogenetics 1997;45:320-4.
14. Jouanolle AM, Gandon G, Blayau M, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:251-2.
15. Rhodes DA, Raha-Chowdhury R, Cox TM, et al. Homozygosity for the predominant Cys282Tyr mutation and the absence of disease expression in hereditary haemochromatosis. J Med Genet 1997;34:761-4.
16. Merryweather-Clarke AT, Worwood M, Parkinson L, et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. B J Haematol 1998;101:369-73.
17. Jackson HA, Carter K, Darke C, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001;114:474-84.
18. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G->A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-18.
19. Deugnier Y, Jouanolle A-M, Chaperon J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis. A study of 9396 French people. Br J Haematol 2002;118:1170-8.
20. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001;2:165-74.
21. Fleming RE, Holden CC, Tomatsu S, et al. Mouse strain differences determine severity of iron accumulation in HFE knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 2001;98:2707-11.
22. Levy JE, Montross LK, Andrewes NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-16.
23. Dupic F, Fruchon S, Bensaid M, et al. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology 2002;122:745-51.
24. Nicolas G, Viatte L, Lou D-Q, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003;34:97-101.
25. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241-7.
26. Fellman V, Rapola J, Pihko H, et al. Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, and aminoaciduria. Lancet 1998;351:490-3.
27. Rotig A, Colonna M, Blanche S, et al. Deletion of blood mitochondrial DNA in pancytopenia. Lancet 1988;2(8610):576-8.
28. Rotig A, de Lonlay P, Chretian D, et al. Aconitase and mitochondrial iron-sulpnur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215-17.
29. Gattermann N, Retzlaff S, Wang Y-L, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome C oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997;90:4961-72.
30. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
31. Petty RK, Harding AE, Morgan-Hughes JA. The clinical features of mitochondrial myopathy. Brain 1986;109:915-38.
32. Griggs RC, Karpati G. Muscle, fatigue, and mitochondropathies. N Engl J Med 1999;341:1077-8.
33. Poulton J, Scott Brown M, Cooper A, et al. A common mitochondrial DNA variant is associated with insulin resistance in adult life. Diabetologia 1998;41:54-8.
34. Poulton J. Does a common mitochondrial DNA polymorphism underlie susceptibility to diabetes and the thrifty genotype? Trends in Genetics 1998;14:387-9.
35. Poulton J, Luan J, Macaulay V, et al. Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet 2002;11:1581-3.
36. Poulton J, Bednarz A, Scott-Brown M, et al. Is the 16189 mitochondrial DNA variant the thrifty gene? Evidence from a population comparison in New Zealand. Diabet Med 1999;16:68.
37. Agani FH, Pichiule P, Chavez JC, et al. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem 2000;275:35863-7.
38. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
39. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000;26:268-70.
40. Cadet E, Capron D, Perez AS, et al. A targetted approach significantly increases the identification rate of patients with undiagnosed hoemochromotosis. J Intern Med 2003;253:217-24.
41. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
42. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Polymorphism in infron 4 of HFE does not compromise haemochromatosis mutation results. Nat Genet 1999;23:271.
43. Worwood M, Jackson HA, Feeney GP, et al. A single tube heteroduplex PCR for the common HFE genotypes. Blood 1999;94:405a.
44. Marchington DR, Poulton J, Sellar A, et al. Do sequence variants in the major non-coding region of the mitochondrial genome influence mitochondrial mutations associated with disease? Hum Mol Genet 1996;5:473-9.
45. Richards MB, Macaulay VA, Bandelt HJ, et al. Phylogeography of mitochondrial DNA in Western Europe. Ann Hum Genet 1998;62:241-60.
46. Richards M, Macoulay V, Hickey E, et al. Tracing European founder lineages in the near Eastern mtDNA pool. Am J Hum Genet 2000;67:1251-76.
47. Casteels K, Ong K, Phillips D, et al. Mitochondrial 16189 variant, thinness at birth and type-2 diabetes, ALSPAC study team. Lancet 1999;353:1499-1500.
48. Piercy R, Sullivan KM, Benson N, et al. The application of mitochondrial DNA typing to the study of while Caucasian genetic identification. Int J Legal Med 1993;106:85-90.
49. Miller KW, Dawson JL, Hagelberg E. A concordance of nucleotide substitutions in the first and second hypervariable segments of the human mtDNA control region. Int J Legal Med 1996;109:107-13.
50. Rolfs A, Kvietikova I, Gassmann M, et al. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272:20055-62.
51. Tacchini L, Bianchi L, Bernelli-Zazzera A, et al. Transferrin receptor induction by hypoxia HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142-6.
52. Qi Y, Jamindar TM, Dawson G. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J Neurochem 1995;64:2458-64.
53. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048-54.
54. Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 2000;278:C92-C101.
55. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia. J Clin Invest 2002;110:1037-44.
56. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003;361:669-73.
57. Roetto A, Papanikoloau G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile haemochromatosis. Nat Genet 2003;33:21-2.
58. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
59. Moraes CT. What regulates mitochondrial DNA copy number in animal cells? Trends in Genetics 2001;17:199-205.
60. Roberti M, Musicco C, Polosa PL, et al. Multiple protein-binding sites in the TAS region of human and rat mitochondrial DNA. Biochem Biophys Res Commun 1998;243:36-40.
61. Morten K, Jen C, Poulton J. The 16189 variant of mtDNA in type 2 diabetes: towards a molecular medicine. Diabet Med 2003;20(suppl 2):13.
62. Atomna H, Walter PB, Ames BN. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. Arch Biochem Biophys 2002;397:345-53.